1. A double-blind placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder;Amsterdam J.D.;Journal of Clinical Psychiatry,2003
2. Blob L.F. & Sharoky M. (2002 October). Safety and efficacy of the selegiline transdermal system for ADHD. Abstract presented at the annual meeting of the American Academy of Child & Adolescent Psychiatry San Francisco CA.
3. Blob L.F. VanDenBerg C.M. Kemper E.M. Ziemniak J.A. Azzaro A.J. & Sharoky M. (2001 May). Safety of selegiline transdermal system: Concomitant administration of pseudoephedrine a sympathomimetic amine. Poster presented at the annual meeting of the New Clinical Drug Evaluation Unit Phoenix AZ.
4. Transdermal selegiline in major depression: A double-blind placebocontrolled parallel-group study in outpatients;Bodkin J.A.;American Journal of Psychiatry,2002
5. Bristol-Myers Squibb Company. (2006). EMSAM ® (selegiline transdermal system). Retrieved May 1 2006 from http://www.bms.com/cgi-bin/anybin. pl?sql=select%20PPI%20from%20TB _PRODUCT_PPI%20where%20PPI_ SEQ=112&key=PPI